Gilda Rossoni

435 total citations
17 papers, 338 citations indexed

About

Gilda Rossoni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Gilda Rossoni has authored 17 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Epidemiology. Recurrent topics in Gilda Rossoni's work include Peptidase Inhibition and Analysis (12 papers), Lung Cancer Research Studies (10 papers) and Neuroendocrine Tumor Research Advances (5 papers). Gilda Rossoni is often cited by papers focused on Peptidase Inhibition and Analysis (12 papers), Lung Cancer Research Studies (10 papers) and Neuroendocrine Tumor Research Advances (5 papers). Gilda Rossoni collaborates with scholars based in Italy and Ukraine. Gilda Rossoni's co-authors include Vanesa Gregorc, Angelo Corti, A. Lambiase, Claudio Bordignon, Giovanni Citterio, Fabrizio Marcucci, Flavio Curnis, Federico Caligaris‐Cappio, Filippo de Braud and Tommaso Martino De Pas and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Gilda Rossoni

16 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gilda Rossoni Italy 7 167 128 106 41 38 17 338
Marta Popęda Poland 13 142 0.9× 156 1.2× 79 0.7× 52 1.3× 13 0.3× 32 350
Marion Gilormini France 5 138 0.8× 169 1.3× 83 0.8× 25 0.6× 53 1.4× 7 329
Jantine PosthumaDeBoer Netherlands 5 105 0.6× 232 1.8× 94 0.9× 24 0.6× 10 0.3× 7 353
Birte Andritzky Germany 8 152 0.9× 187 1.5× 91 0.9× 42 1.0× 31 0.8× 13 350
Martine Bocchini Italy 7 110 0.7× 60 0.5× 167 1.6× 17 0.4× 78 2.1× 13 318
Seog Young Kim South Korea 7 203 1.2× 129 1.0× 33 0.3× 68 1.7× 56 1.5× 9 327
Conall Hayes Ireland 8 247 1.5× 139 1.1× 76 0.7× 179 4.4× 17 0.4× 16 447
Michael Zepp Germany 13 162 1.0× 179 1.4× 32 0.3× 109 2.7× 13 0.3× 25 386
Svetlana Miklikova Slovakia 12 168 1.0× 202 1.6× 45 0.4× 48 1.2× 16 0.4× 17 401
Christoph Wilmanns Australia 5 150 0.9× 116 0.9× 31 0.3× 32 0.8× 27 0.7× 6 320

Countries citing papers authored by Gilda Rossoni

Since Specialization
Citations

This map shows the geographic impact of Gilda Rossoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gilda Rossoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gilda Rossoni more than expected).

Fields of papers citing papers by Gilda Rossoni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gilda Rossoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gilda Rossoni. The network helps show where Gilda Rossoni may publish in the future.

Co-authorship network of co-authors of Gilda Rossoni

This figure shows the co-authorship network connecting the top 25 collaborators of Gilda Rossoni. A scholar is included among the top collaborators of Gilda Rossoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gilda Rossoni. Gilda Rossoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Corti, Angelo, Flavio Curnis, Gilda Rossoni, Fabrizio Marcucci, & Vanesa Gregorc. (2013). Peptide-Mediated Targeting of Cytokines to Tumor Vasculature: The NGR-hTNF Example. BioDrugs. 27(6). 591–603. 58 indexed citations
3.
Bulotta, Alessandra, Vanesa Gregorc, Gilda Rossoni, et al.. (2013). Relationships of peripheral blood lymphocyte counts (PBLC) with antitumor activity of NGR-hTNF given in combination with chemotherapy (CT).. Journal of Clinical Oncology. 31(15_suppl). 3038–3038. 2 indexed citations
4.
Gregorc, Vanesa, Nicoletta Zilembo, Francesco Grossi, et al.. (2013). Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 31(15_suppl). 8035–8035. 2 indexed citations
5.
Bearz, Alessandra, Renato Talamini, Gilda Rossoni, et al.. (2012). Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Research Notes. 5(1). 482–482. 33 indexed citations
6.
Rossoni, Gilda, Vanesa Gregorc, Maria Grazia Viganò, et al.. (2012). NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology. 30(15_suppl). 7076–7076. 2 indexed citations
7.
Vincenzo, Fabio De, Gilda Rossoni, Antonio Santoro, et al.. (2011). NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM) .. Journal of Clinical Oncology. 29(15_suppl). 7089–7089. 4 indexed citations
8.
Zilembo, Nicoletta, Francesco Grossi, Gilda Rossoni, et al.. (2011). 9014 POSTER DISCUSSION Randomized Phase II Trial of NGR-hTNF and Chemotherapy in Chemo-naive Patients With Non-small Cell Lung Cancer (NSCLC) -Preliminary Results. European Journal of Cancer. 47. S596–S596. 1 indexed citations
9.
Gregorc, Vanesa, Filippo de Braud, Tommaso Martino De Pas, et al.. (2011). Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors. Clinical Cancer Research. 17(7). 1964–1972. 44 indexed citations
10.
Viganò, Maria Grazia, Raffaele Cavina, Silvia Novello, et al.. (2011). Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC).. Journal of Clinical Oncology. 29(15_suppl). 7077–7077. 5 indexed citations
11.
Santoro, Armando, Tiziana Pressiani, Giovanni Citterio, et al.. (2010). Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. British Journal of Cancer. 103(6). 837–844. 29 indexed citations
12.
Gregorc, Vanesa, Paolo Andrea Zucali, Armando Santoro, et al.. (2010). Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 28(15). 2604–2611. 91 indexed citations
13.
Gregorc, Vanesa, Giovanni Citterio, Giordano Vitali, et al.. (2009). Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. European Journal of Cancer. 46(1). 198–206. 47 indexed citations
14.
Santoro, Armando, Giovanni Citterio, Tiziana Pressiani, et al.. (2009). 6617 Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC). European Journal of Cancer Supplements. 7(2). 395–395. 1 indexed citations
15.
Citterio, Giovanni, Armando Santoro, Tiziana Pressiani, et al.. (2008). A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 26(15_suppl). 15544–15544. 1 indexed citations
16.
Berti, F. & Gilda Rossoni. (1991). Pathophysiology of coronary vasomotor tone.. PubMed. 36(12 Suppl 1). 139–42. 1 indexed citations
17.
Melillo, G., S Malandrino, Gilda Rossoni, et al.. (1988). General pharmacology of the new antitussive levodropropizine.. PubMed. 38(8). 1144–50. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marta Popęda Breakdown of academic impact, for papers by Marion Gilormini Breakdown of academic impact, for papers by Jantine PosthumaDeBoer Breakdown of academic impact, for papers by Birte Andritzky Breakdown of academic impact, for papers by Martine Bocchini Breakdown of academic impact, for papers by Seog Young Kim Breakdown of academic impact, for papers by Conall Hayes Breakdown of academic impact, for papers by Michael Zepp Breakdown of academic impact, for papers by Svetlana Miklikova Breakdown of academic impact, for papers by Christoph Wilmanns
Rankless by CCL
2026